VentiRx Pharmaceuticals, Inc.

Celgene Corp. 's aggressive deal-making strategy could pay off in a big way over the next several years, bringing in billions of dollars in annual sales from new drugs to diversify revenue beyond its

Known for its creative partnering savvy, Celgene Corp. has transformed itself into a serious contender in immuno-oncology through two key partnerships, spending nearly $1.5 billion upfront across

As an industry, biopharma actually fares pretty well when it comes to taxes. Among profitable companies, biotech and pharma have some of the lowest effective U.S. tax rates compared to companies in ot

Big pharma, small biotech and academic institutions are experimenting with new ways of working together, and San Diego's life science industry group Biocom invited deal makers to town on 26 and 27 Feb